Haemostatic drug - Thrombotargets Corp

Biotecnología
Pathway screening

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

Haemostatic drug

Know the novel TT-103MH, the haemostatic drug by Thrombotargets. It is a new way for treating topically all kinds of bleeding. See here the characteristics of this revolutionary haemostatic drug.

Platelet procoagulant

Solution for haemorrhage induces by anticoagulant and anti platelet therapies. Thrombotargets Biotech Corporation has developed a procoagulant drug call TT-103MH to stop bleeding topically.

Hemostatic drug

Know the novel hemostatic drug generation TT-103MH got through BioplatformScreen by Thrombotargets. For topical treatment of bleeding disorders.

Hemophiliac

TT-103MH is a new recombinant protein developed for use in the treatment of non-life threatening mild-to-severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliacs. It has been observed to prevent death in a lethal model of hemophilia in mice; TT-103MH also reduced blood coagulation time up to 90% in ex vivo studies using hemophiliac blood.

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.